IloprostDrugs Market, By Route of Administration (Intravenous, and Inhalation), ByDistribution Channel (Hospital Pharmacies, Retail Pharmacies, and OnlinePharmacies), By Region (North America, Latin America, Europe, Asia Pacific,Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019- 2027
Iloprost is a drug used fortreating diseases such as pulmonary arterial hypertension, scleroderma, Raynaudsyndrome, and other conditions where constriction in blood vessels and improperblood flow in tissues is found. The trade name of the drug is Ventavis orIlomedine. Iloprost, which received approval by the U.S. Food and DrugAdministration (FDA) in 2004 for pulmonary arterial hypertension.
Iloprost dilates the narrowedblood vessels (arteries) in lungs which results in decreased pulmonary bloodpressure to the heart. The drug can be administered either through infusion orit can be inhaled using nebulizers. The infusion is administered intravenouslywhich lasts for about six hours in a day and the session is repeated for threeto five days in a row whereas the inhalations should be done six to nine timesin a day, according to the physician’s prescription.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3284
Global Iloprost Drugs Market –Dynamics
Increasing prevalence ofpulmonary arterial hypertension is expected to propel the market growth overthe forecast period. For instance, according to the National Organization forRare Disorder (NORD), 2018, nearly 500 to 1000 new cases of pulmonary arterialhypertension are diagnosed each year in the U.S.
Moreover, various merges,agreements and acquisitions of major companies are likely to propel the marketgrowth. For instance, in January 2017, Acetlion announced that Johnson &Johnson will be acquiring the firm including its marketed products in pulmonaryarterial hypertension franchise.
Furthermore, increasing number ofplayers are focusing on developing this drug, in order to, which is alsocontributing to the market growth over the forecast period. For instance, in2018, according to the National Institute of Health, approximately15 clinicaltrials involving Iloprost were active globally. For instance, in November 2015,the National Cancer Institute initiated a phase I clinical trial for evaluatingiloprost in preventing recurrence of lung cancer for patients who smoke and thestudy is expected to complete in 2020.
However, the drug has some sideeffects such as kidney failure, dyspnea, chest pain, short breath, and swellingof limbs. The above stated side effects are expected to restrain the market growthover the forecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/iloprost-drugs-market-3284
Global Iloprost Drugs Market –Regional insights
North America accounted for thelargest market share in 2018, owing to mergers, agreements, and acquisitions bykey players in the region. For instance, in August 2019, VisionGate, a U.S.-based oncology pharmaceutical and diagnostics company, received an exclusiveworldwide right and license from Bayer AG for the technology to develop,manufacture, sale, and commercialize iloprost betadex clathrate in the field oflung cancer treatment and prevention. Also, in 2012, Bayer AG collaborated withVectura to develop Breelib, which is a hand held nebulizer device designed forimproved delivery of Bayer’s Ventavis (iloprost).
Global Iloprost Drugs Market -Competitive Landscape
Key manufactures in the marketinclude Actelion Pharmaceuticals, Bayer AG, Vectura Group Plc., and VisionGate.Moreover, key players in market are focused on developing new products, inorder to enhance their market share. For instance, in 2017, Bayer AG andVectura Group Plc. extended their collaboration again to develop an upgradedversion of nebulizer Breelib which improves the efficacy of iloprost aerosoltherapy in pulmonary atrial hypertension. According to the National Instituteof Health, the nebulizer is still in clinical trial and the study is expectedto finish in March 2020.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3284
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
